Skip to main content

Recurrent Osteosarcoma clinical trials at UCSF

12 in progress, 2 open to eligible people

Recurrent osteosarcoma is a bone cancer that returns after being treated. UCSF is researching two medicines, CBL0137 and tegavivint, to find safe doses and monitor possible side effects. These studies include people with other solid tumors and lymphomas.

Showing trials for

Our lead scientists for Recurrent Osteosarcoma research studies include .

Last updated: